Situation - One of the LPs required some quant and qual research to understand prescribing accelerators and decelerators of medicinal cannabis in a certain neurodegenerative disorder
Target - Specialist nurses
Approach - we undertook a cost effective phone based interview amongst the Target, sponsor blinded
Outcome - laid a solid foundation for understanding of Rx accelerators and decelerators to help efficiently structure future marketing approach
Case 2 - Launching in Neurology
Case 2 - Launching in Neurology
Case 2 - Launching in Neurology
Situation - A large cap Biotech Client was entering a new therapeutic area in which no institutional knowledge existed
Target - Specialist KOL physicians, nurses, and community specialists
Approach - our group was retained to work on the multi year pre launch and launch as we had extensive national KOL contacts and expertise in this therapeutic area. We developed and implemented, over several years, a layered and progressively building series of Consultant Meetings
Outcome - our approach was a key factor in building advocacy and accelerating prescriptions at launch
Case 3 - USA Hematology Launch
Case 2 - Launching in Neurology
Case 4 - Evidence-based Analysis
Situation - A small, niche Pharma client was launching a rare disorder drug in the USA with a very poor label, missing many salient evidence sets (survival data) supporting the brand and messaging
Target - Specialist KOLs and nurses
Approach - A series of progressively building advisory boards used as a compliant platform to help share and discuss clinically relevant data that fell outside of the approved label
Outcome - increased and accelerated brand uptake due to greater understanding of the risks and more notably, benefits of the client's therapy
Case 4 - Evidence-based Analysis
Case 6 - Established Cancer Brand
Case 4 - Evidence-based Analysis
Situation - A large cap Biotech Client was entering a new space where no institutional knowledge existed and wanted to get an early understanding and foundation of the competitive sets of established rivals
Target - N/A
Approach - Our group developed an evidence-based review of the medical literature supporting the brand organized in a P.I.C.O.S format as well as CDR / Provincial reimbursement criteria
Outcome - these materials helped identify the Client's potential competitive differentiation in the marketplace and are used amongst multiple stakeholders for commercial, training, and medical education purposes.
Case 5 - KOL Digital Portal
Case 6 - Established Cancer Brand
Case 6 - Established Cancer Brand
Situation - Our large cap Biotech Client has a brand in a highly competitive space and wanted a means to continue the dialogue with their KOLs who form their advisory board
Target - Specialist KOLs and nurses
Approach - We developed a super-easy digital portal that was used by the Target at regular intervals post advisory board meeting as a vehicle to stay top of mind and obtain continuous feedback
Outcome - We achieved almost 100% participation rate amongst the Target and developed deeper relationships and insights into the behaviours driving brand prescriptions and loyalty
Case 6 - Established Cancer Brand
Case 6 - Established Cancer Brand
Case 6 - Established Cancer Brand
Situation - A large cap Biotech Client with a mature oncology brand where the delivery of care was heterogeneous with some centers not following the latest published treatment guidelines, where the Client's brand was an important part of the treatment regimen
Target - Specialist KOL physicians
Approach - We used a number of regional advisory boards, leveraging peer-to-peer influence, to work towards homogenizing treatment protocols across centres and leveraging evidence-based treatment guidelines
Outcome - the regional peer-to-peer programs influenced the modernization of treatment protocols at a local level, resulting in increased utilization of the Client's brand
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.